Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Inclusion Criteria * Males and females of at least 18 years of age with metastatic RCC of predominantly clear cell histology who have received 0 to 2 prior treatment regimens for metastatic disease. * Measurable disease according to Response Criteria for Solid Tumors. * Negative pregnancy test (women of childbearing potential only). * Pretreatment laboratory levels that meet specific criteria. * Signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations * Patients must have failed at least one approved or investigational tyrosine kinase inhibitor (TKI). Exclusion Criteria * Any of the following histologies of RCC: papillary, chromophobe, collecting duct, or unclassified. * Known sensitivity to murine proteins or chimeric antibodies or other components of the product. * Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer). * Systemic chemotherapy, immunotherapy, radiation therapy, or monoclonal antibody therapy within 4 weeks of M200 administration. * Documented central nervous system (CNS) tumor or CNS metastasis. * History of thromboembolic events and bleeding disorders within the past year. * Medical conditions that may be exacerbated by bleeding.